Vima Therapeutics vs Vivtex
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $100M Series A extended ($60M + $40M add-on after clinical data) from Atlas, Frazier, Access Industries. Only oral drug in development for isolated dystonia. Phase 2 in dystonia and Parkinson's in 2026.
About
Vima Therapeutics is developing VIM0423, the only oral drug in clinical development for isolated dystonia — a movement disorder characterized by involuntary, sustained muscle contractions affecting approximately 160,000 people in the US, with zero FDA-approved oral treatment options. The company raised a $100 million Series A (extended from $60 million to $100 million after positive clinical data) from Atlas Venture, Frazier Life Sciences, and Access Industries. VIM0423 is entering Phase 2 trials in both isolated dystonia and Parkinson's disease tremor in 2026.
Signed $2.1B Novo Nordisk collaboration (Feb 2026). Platform enables oral delivery of proteins and peptides (historically injection-only). MIT Langer lab spinout.
About
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historically required injection because they are degraded by stomach acid and too large to absorb through the intestinal wall. In February 2026, Vivtex signed a $2.1 billion collaboration agreement with Novo Nordisk for the development of oral formulations of biologic drugs in obesity, diabetes, and metabolic disease.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.